Gene G. Kinney Sells 8,548 Shares of Prothena Corp. (PRTA) Stock
Prothena Corp. (NASDAQ:PRTA) insider Gene G. Kinney sold 8,548 shares of the stock in a transaction dated Wednesday, November 9th. The shares were sold at an average price of $55.32, for a total transaction of $472,875.36. Following the completion of the transaction, the insider now directly owns 11,341 shares in the company, valued at $627,384.12. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Shares of Prothena Corp. (NASDAQ:PRTA) opened at 63.60 on Monday. The company’s 50 day moving average is $55.15 and its 200 day moving average is $50.07. The firm’s market cap is $2.19 billion. Prothena Corp. has a 52-week low of $28.20 and a 52-week high of $76.42.
Prothena Corp. (NASDAQ:PRTA) last announced its quarterly earnings data on Tuesday, November 1st. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($1.22) by $0.04. The company earned $0.29 million during the quarter, compared to the consensus estimate of $0.49 million. Prothena Corp. had a negative return on equity of 32.65% and a negative net margin of 11,365.41%. Analysts anticipate that Prothena Corp. will post ($4.36) earnings per share for the current year.
Several research analysts have weighed in on the stock. Wedbush reissued an “outperform” rating and issued a $77.00 price target on shares of Prothena Corp. in a report on Thursday. Zacks Investment Research raised shares of Prothena Corp. from a “sell” rating to a “hold” rating in a report on Friday, November 4th. Deutsche Bank AG initiated coverage on shares of Prothena Corp. in a report on Thursday, November 3rd. They issued a “buy” rating and a $73.00 price target on the stock. Credit Suisse Group AG restated a “buy” rating and set a $65.00 target price on shares of Prothena Corp. in a research report on Tuesday, September 27th. Finally, Barclays PLC increased their target price on shares of Prothena Corp. from $60.00 to $70.00 and gave the stock an “overweight” rating in a research report on Thursday, August 4th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Prothena Corp. has a consensus rating of “Buy” and a consensus price target of $76.17.
Hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP raised its stake in shares of Prothena Corp. by 29.0% in the first quarter. Wellington Management Group LLP now owns 3,216,685 shares of the company’s stock valued at $132,398,000 after buying an additional 722,889 shares in the last quarter. BlackRock Fund Advisors raised its stake in shares of Prothena Corp. by 5.6% in the third quarter. BlackRock Fund Advisors now owns 1,337,144 shares of the company’s stock valued at $80,189,000 after buying an additional 71,287 shares in the last quarter. State Street Corp raised its stake in shares of Prothena Corp. by 51.3% in the first quarter. State Street Corp now owns 1,224,523 shares of the company’s stock valued at $50,406,000 after buying an additional 415,089 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in shares of Prothena Corp. by 3.2% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 875,767 shares of the company’s stock valued at $52,520,000 after buying an additional 26,842 shares in the last quarter. Finally, Palo Alto Investors LLC raised its stake in shares of Prothena Corp. by 13.4% in the second quarter. Palo Alto Investors LLC now owns 788,618 shares of the company’s stock valued at $27,570,000 after buying an additional 93,100 shares in the last quarter.
About Prothena Corp.
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).
Receive News & Stock Ratings for Prothena Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corp. and related stocks with our FREE daily email newsletter.